NCT04675528已完成1 期
A Randomized, Open-label, Two-way Crossover Clinical Trial to Evaluate the Food Effect on Pharmacokinetics and SafEty of DHP107 (Oral Paclitaxel, Liporaxel®) in Patients With Advanced Solid Tumors (FEEL) / EudraCT no : 2020-004976-16
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 5
- 主要终点
- • Cmax
研究概览
简要总结
To evaluate the food effect on pharmacokinetics of DHP107 in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are ≥18 years of age on the date of written informed consent.
- •Subjects with histologically or cytologically confirmed advanced solid tumors including but not limited to the listed below for which paclitaxel monotherapy has been determined an appropriate therapy at the investigator's discretion.
- •Angiosarcoma
- •Bladder cancer
- •Breast cancer
- •Cervical cancer
- •Head and neck cancer (if no difficulty with swallowing)
- •Kaposi's sarcoma
- •Lung cancer
- •Ovarian cancer
- •Subjects who have a life expectancy of ≥12 weeks.
- •Subjects who are able to take oral medication.
- •Subjects who have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale.
- •Subjects who have evaluable disease according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1).
- •Subjects who have adequate organ functions as indicated by the following laboratory values:
- •Subjects who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and procedures.
- •Subjects who have voluntarily agreed to participate by giving written informed consent.
- •Women of childbearing potential who have negative pregnancy test results at the screening visit and men with female partners of childbearing potential must agree to use adequate contraception for the duration of the trial and up to 90 days after last dose of study drug
排除标准
- •Subjects who have history of severe hypersensitive reaction to the active ingredient or any excipients of DHP
- •Subjects with following surgical history/medical conditions that may affect drug absorption:
- •Subjects who developed cardiovascular disease (unstable angina, myocardial infarction, stroke, and transient ischemic attack) within 24 weeks prior to study entry, which is deemed to be clinically significant by the investigator.
- •Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection (However, subjects with Gilbert's Syndrome, asymptomatic gallstones, or stable chronic liver disease are, at the discretion of the investigator, eligible for the study. Subjects who are hepatitis B carriers may be eligible if they are on antiviral therapy 2 weeks prior to study entry).
- •Subjects with neuropathy grade > 2 based on CTCAE v5.0 at the time of study entry.
- •Subjects with uncontrolled medical or mental illness that, in the investigator's judgement, could affect treatment tolerability or compliance.
- •Subjects diagnosed with other malignant primary tumor with an exception of the following:
- •Malignancy diagnosed at least 5 years previously without evidence of recurrence or persistent disease
- •The complete excision of basal/squamous cell carcinoma or papillary thyroid carcinoma or the complete treatment of cervical intraepithelial neoplasia or other in situ carcinoma
- •Subjects with symptomatic or unstable, untreated metastases to the central nervous system (CNS) at the time of screening ('Unstable' means worsening of symptoms within 4 weeks prior to screening).
- •Subjects who are currently receiving alternative cytotoxic agents, regular systemic corticosteroids and medications that could influence drug absorption (e.g. H2-antihistamines, antacids, metoclopramide and charcoal) within 4 weeks prior to entry into the study (C1D1).
- •Subjects who are currently receiving (or unable to stop use the 3 days before the first dose of DHP107 and throughout the study) prescription or non-prescription medications or other products known to be moderate or potent inhibitors/inducers of CYP3A4, P-gp, or CYP2C
- •Subjects who cannot intake whole high fat meal offered.
- •Pregnant or breastfeeding women.
- •Subjects who have received any investigational drugs or devices within 4 weeks before the first day of study treatment (C1D1)
研究组 & 干预措施
Fasting treatment
Experimental
干预措施: DHP107(Oral paclitaxel) (Drug)
Fed treatment
Experimental
干预措施: DHP107(Oral paclitaxel) (Drug)
结局指标
主要结局
• Cmax
时间窗: Day 1 and Day 8 of Cycle 1(each cycle is 28 days)
The primary endpoints of this trial are the ratio of geometric means of the following pharmacokinetic parameters following DHP107 administration fed with fasting condition
• Tmax
时间窗: Day 1 and Day 8 of Cycle 1(each cycle is 28 days)
and the median difference of the following pharmacokinetic parameters following DHP107 administration fed with fasting condition:
次要结局
未报告次要终点
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
不适用
Pharmacokinetic Study for Anti-tuberculosis DrugsPulmonary TuberculosisNCT00948077Taipei Medical University WanFang Hospital16
招募中
1 期
To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004HealthyNCT06431399Jeil Pharmaceutical Co., Ltd.36
已完成
1 期
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy SubjectsHealthy VolunteerNCT04204629Hanmi Pharmaceutical Company Limited25
已完成
1 期
Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese VolunteersHealthy VolunteersNCT05249348PMV Pharmaceuticals, Inc34
已完成
1 期
A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese VolunteersSchizophreniaNCT00892320Johnson & Johnson Pharmaceutical Research & Development, L.L.C.20